Pfizer Inc mulls buying Strides Arcolab’s ‘Agila Specialties’ for $2bn: Reports

15 Jan 2013 Evaluate

Pfizer Inc is reportedly mulling to buy Strides Arcolab’s medicines unit, Agila Specialties, for a possible price of $2 billion or Rs 10,886.31 crore. Further, towards this development, Pfizer is currently conducting due diligence and a deal could be reached this quarter.

Strides Arcolab, a supplier of cancer-fighting drugs to Pfizer Inc, has been considering selling its injectable medicines unit since August, 2012. Meanwhile, Agila uptill now has also drawn interest from Canonsburg, Pennsylvania-based Mylan Inc., Swiss drugmaker Novartis AG (NOVN), and Fresenius SE, which is based in Bad Homburg, Germany. Basically, Agila’s relative success in winning approvals for new products and the scarcity of facilities that manufacture injectable medicines made it an attractive target for drug makers.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

Strides Pharma Scien Share Price

942.00 -8.50 (-0.89%)
05-Jul-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1568.85
Dr. Reddys Lab 6536.00
Cipla 1509.40
Zydus Lifesciences 1162.40
Lupin 1769.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.